SmithKline Beecham Consumer Healthcare (SBCH) dominates the Rs 13 bn Indian malted beverage market with over 65% share. Its brand ‘Horlicks’ has led to growth of this sector in India. The company’s other brands include ‘Boost’, ‘Viva’ and ‘Maltova’. SBCH has a strong marketing and distribution network in India comprising over 1,600 wholesalers and direct coverage of over 400,000 retail outlets.
Since 1990, SBCH has grown at an impressive CAGR of 21% both in terms of topline and bottomline. In a difficult year like 2001, SBCH has so far managed to record a 16% growth in topline and a 17% growth in bottomline. Moreover, the malted beverage penetration is still around 15%, which is a sign of immense potential for this market.
In the previous five years the company’s turnover has grown at a CAGR of 15% and net profits at a CAGR of 24%. These figures are by far among the best growth rates posted by an FMCG company. Its EPS has almost doubled in the last four years to Rs 24.7. Its exports accounted for around 4% of its FY01 sales.
That SBCH is buoyant on India’s market potential is evident from the fact that it spent Rs 2.4 bn on a new plant (26,000 tonnes per annum) to manufacture Horlicks. The company has increased capacity at its existing plant by 6,000 tonnes per annum. Productivity level is expected to improve substantially, as the new plant is based on the latest available technology.
Among the concerns is the fact that SBCH pays 4% of its revenues as a royalty to its parent company on sale of Horlicks. The parent has introduced all the new brands in India through its 100% subsidiary SmithKline Beecham Asia Pvt. Ltd. The subsidiary has well known brands like ‘Aquafresh’ in oral care segment, ‘Eno’ and ‘Crocin’ in the OTC pharma portfolio. SBCH receives only the marketing fees of around 5% for these products.
However, the subsidiary concerns have been allayed to a certain extent, as the parent has not shown any lack of focus even post Glaxo’s worldwide merger with SmithKline. Among the recent developments, GlaxoSmithKline Pharmaceutical Limited has transferred the promotion, marketing and distribution activities of ‘Iodex’ range of products to SBCH with effect from January 2002. The ‘Iodex’ brand is estimated to have a turnover of about Rs 700 m. Taking an estimated 5% marketing fee, this is likely to add Rs 35 m to SBCH’s bottomline in 2002.
The company seems likely to continue growing at historical rates, owing solely to its market dominance of India’s malted beverage market. The stock touched its 52 week high of Rs 448 in September first week and is currently trading at Rs 400. At the current price, the stock’s P/E rating stands at 14x FY02E earnings and market cap to sales ratio of 2x. The valuations are on the lower side of the FMCG spectrum owing to its subsidiary concerns. But even if the parent does not introduce new products through SBCH, the company already has a lot on its plate in terms of generating growth from malted drinks in India.
GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407